Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

58.83USD
20 Apr 2018
Change (% chg)

$0.19 (+0.32%)
Prev Close
$58.64
Open
$58.86
Day's High
$59.27
Day's Low
$58.67
Volume
3,825,368
Avg. Vol
3,915,961
52-wk High
$66.41
52-wk Low
$52.83

Chart for

About

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes... (more)

Overall

Beta: 0.83
Market Cap(Mil.): $176,050.70
Shares Outstanding(Mil.): 2,727.35
Dividend: 0.47
Yield (%): 2.91

Financials

  MRK.N Industry Sector
P/E (TTM): 35.16 30.95 32.74
EPS (TTM): 1.84 -- --
ROI: 6.58 14.84 14.38
ROE: 12.28 16.34 16.07

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

UPDATE 2-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON, April 20 Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

20 Apr 2018

BRIEF-Merck Announces First Phase 3 Studies For Pcv-15 (V114), Its Investigational Pneumococcal Disease Vaccine

* MERCK ANNOUNCES FIRST PHASE THREE STUDIES FOR PCV-15 (V114) ITS INVESTIGATIONAL PNEUMOCOCCAL DISEASE VACCINE

17 Apr 2018

BRIEF-Labcyte Reaches Agreement With Merck To Supply Acoustic-Mass Spectrometry Equipment

* LABCYTE REACHES AGREEMENT WITH MERCK TO SUPPLY ACOUSTIC-MASS SPECTROMETRY EQUIPMENT

17 Apr 2018

Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

16 Apr 2018

UPDATE 2-Survival data boosts Merck's Keytruda lead in lung cancer

NEW YORK/CHICAGO, April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.

16 Apr 2018

Merck, Bristol-Myers immunotherapies impress in key lung cancer trials

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.

16 Apr 2018

Wall Street rises but pares gains late after report of FBI raid

NEW YORK Wall Street's major indexes rose on Monday as a softer stance by U.S. policymakers on China tariffs powered a rebound from last week's selloff, but stocks pared much of their gains late in the session after a report that the Federal Bureau of Investigation raided the office of President Donald Trump's lawyer. | Video

09 Apr 2018

US STOCKS-Wall St rises but pares gains late after report of FBI raid

* Indexes up: Dow 0.2 pct, S&P 0.3 pct, Nasdaq 0.5 pct (Updates to close)

09 Apr 2018

Competitors

Earnings vs. Estimates